Generally speaking, Medtronic's (NYSE:MDT) in the same boat as every other large-cap med-tech stock, where valuation has been compressed by worries about long-term growth prospects. Like Covidien (NYSE:COV), Johnson & Johnson (NYSE:JNJ) and a handful of select others, Medtronic seems to be past the worst of the growth lull, and the company has several potentially major products lined up in the pipeline. Now the real question for investors is the extent to which this quarter's growth can be sustained and whether the Street will come back and take a fancy to the significant cash flow this company generates.

Applying The MACD Indicator With MetaTrader 4: How to use MetaTrader 4, a trading platform used for online trading in the forex, CFD and futures markets.

Fiscal Second Quarter Results Good on Growth, but not Margins
Medtronic reported 2% growth for its fiscal quarter (ex-Physio), while organic growth was a strong 4.5%. Medtronic's three largest businesses were pretty mixed; cardiac rhythm management (CRM) was flat in constant currency terms (with ICDs just positive and atrial fibrilation up more than 20%), Cardio was up almost 13%, and Spine was down more than 5%.

Medtronic's smaller businesses all delivered pretty solid growth. Neuromodulation was up about 10%, Diabetes was up almost 6% (with international sales up in the mid teens), and SurgTech was up 17% (and up 13% organically).

Medtronic's margin performance was less stellar. Gross margin missed management's guidance and the average sell-side estimate by about half a point, dropping about 40 basis points from last year and 60 from the prior quarter. That miss basically flowed through the operating line, as operating income fell more than 2%, operating margin contracted by half a point and Medtronic missed the average Street bogey by about 70 basis points.

Is This Growth Sustainable?
Perhaps the biggest concern for this quarter is whether this gaudy (for a large med-tech company, at least) organic growth is sustainable. Medtronic saw about 34% growth from its drug-coated stent business, and the launch of the Resolute stent appeared to account for almost half of the reported organic growth.

With that sales burst likely to fade, and rivals Abbott Labs (NYSE:ABT) and Boston Scientific (NYSE:BSX) certain to respond, it's a worthwhile question. Likewise, while Medtronic gained share from Boston Sci and St. Jude (NYSE:STJ) in CRM and is seeing better conditions in spine, I'm not sure these three large enterprises are ever going to be major growers again.

By the same token, I don't also don't think CRM and spine are likely to get much worse. That opens the door to ongoing improvements in other businesses. Neuromodulation and diabetes care continue to be growth opportunities for Medtronic (Medtronic saw good OUS growth in diabetes at a time when many rivals, including Abbott and JNJ are having their challenges), and so too does SurgTech.

The bigger question(s) for Medtronic shareholders probably revolve around transcatheter heart valve implantation (TAVI), renal denervation and emerging markets. On the TAVI side, Edwards Lifesciences (NYSE:EW) isn't surrendering an inch on the IP litigation front, while budgetary worries in Europe appear to be pressuring growth right now. Renal denervation still looks like a multi-billion dollar opportunity, but St. Jude, Covidien, Boston Sci, and (likely) JNJ are not going to give Medtronic any breathing room. On the emerging market side, Medtronic made an aggressive but expensive move in acquiring China Kanghui, but there's still work to do in markets such as Brazil, Russia, and India.

The Bottom Line
For a little while now I've been bullish on Medtronic's stock, as I do believe the company is close to a point where the CRM and spine businesses are likely to turn around. What's more, the company is exceptionally profitable and ridiculously good at converting revenue into free cash flow. Medtronic is going to have work increasingly hard to grow revenue, but I see the company as being more apt to continue to do relatively smaller deals (like CoreValve and Ardian) as opposed to bigger splashes like JNJ's deal for Synthes or Hologic's (Nasdaq:HOLX) deal for Gen-Probe.

Right now, I build my discounted cash flow model for Medtronic around the assumption of 2-3% long-term revenue growth and improvements in free cash flow conversion sufficient to add another 1-2% to free cash flow growth. With that sort of growth, fair value would seem to lie in the mid-$50s, making Medtronic a stock worthy of consideration for value, GARP, and dividend growth investors.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center